Alterity Therapeutics Presents Positive ATH434 Data
Ticker: PRNAF · Form: 6-K · Filed: Oct 9, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, clinical-data, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K showing positive data for ATH434, potentially good news for the stock.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on October 9, 2025, to incorporate by reference into several of its SEC registration statements. The filing includes Exhibit 99.1, which details positive results for its drug candidate ATH434.
Why It Matters
Positive clinical data for ATH434 could advance Alterity's pipeline and potentially lead to new treatments for neurological disorders.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the positive data for ATH434 implies potential future developments that carry inherent clinical and regulatory risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- ATH434 (drug_candidate) — Subject of positive results
- October 9, 2025 (date) — Filing date
- 333-251073 (registration_statement_file_number) — Incorporated by reference
- 333-248980 (registration_statement_file_number) — Incorporated by reference
- 333-228671 (registration_statement_file_number) — Incorporated by reference
- 333-274816 (registration_statement_file_number) — Incorporated by reference
- 333-251647 (registration_statement_file_number) — Incorporated by reference
- 333-231417 (registration_statement_file_number) — Incorporated by reference
- 333-250076 (registration_statement_file_number) — Incorporated by reference
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
What is the filing date of this report?
The filing date is October 9, 2025.
What is the name of the company filing this report?
The company filing is Alterity Therapeutics Limited.
What is being incorporated by reference into the registration statements?
Exhibit 99.1, which details positive results for ATH434, is being incorporated by reference.
What is the primary business address of Alterity Therapeutics Ltd. listed in the filing?
The primary business address is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 194 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-10-09 06:33:24
Filing Documents
- ea0260765-6k_alterity.htm (6-K) — 13KB
- ea026076501ex99-1_alterity.htm (EX-99.1) — 30KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-097570.txt ( ) — 65KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 9 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Presents Positive ATH434 Data at 2025 MDS Congress 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 9, 2025 2